Share on facebook Share on Twitter Share on Google Plus Share This

Coronary Artery Disease

Coronary Artery Disease (CAD) happens when the arteries that send blood to the heart muscle harden and narrow.  CAD is the most common type of heart disease in the United States.

Doctors + Care Team

Andrew R. Weintraub, MD

Andrew R. Weintraub, MD

Title(s): Associate Director, Interventional Cardiology and Vascular Center; Medical Director, Valvular and Structural Heart Health Center; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-6140
Fax #: 617-636-2276

Interventional cardiology, vascular medicine, peripheral vascular intervention

View Full Profile

Ayan R. Patel, MD

Ayan R. Patel, MD

Title(s): Director, Cardiovascular Imaging and Hemodynamic Laboratory; Director, Women's Heart Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-8070

Echocardiography, heart failure, women's heart disease

View Full Profile

Carey D. Kimmelstiel, MD

Carey D. Kimmelstiel, MD

Title(s): Director, Interventional Cardiology Center; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-5913

Interventional cardiology

View Full Profile

Laurence A. Conway, MD

Laurence A. Conway, MD

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8252
Fax #: 617-636-5039

Interventional cardiology

View Full Profile

Mohamad El-Zaru, MD

Mohamad El-Zaru, MD

Title(s): Staff Cardiologist, Interventional Cardiology Center; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8252
Fax #: 617-636-5039

Cardiovascular disease

View Full Profile

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Navin K. Kapur, MD, FAHA, FACC, FSCAI

Title(s): Executive Director, The CardioVascular Center for Research and Innovation (CVCRI); Director, Acute Mechanical Circulatory Support Program; Director, Interventional Research Laboratories; Investigator, Molecular Cardiology Research Institute (MCRI); Associate Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8252
Fax #: 617-636-5913

Interventional cardiology, advanced heart failure, mechanical circulatory support

View Full Profile

Research + Clinical Trials


HeartMate PHP™ Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 60 sites in the US. Control device will be the Abiomed Impella® Recover® LP 2.5 Percutaneous Cardiac Support System.

Additionally, the study will include a nonrandomized roll-in phase at each site. Each site must first enroll and treat up to 3 patients in the nonrandomized roll-in phase before entering the randomized phase.

Assess the safety and efficacy of the HeartMate PHP in supporting patients with severe symptomatic coronary artery disease with diminished but stable cardiovascular function, who are undergoing elective or urgent high risk percutaneous coronary interventions (PCI) but are not candidates for coronary artery bypass graft (CABG) surgery.

Proposed Indications The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent,

hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.  Nonrandomized Roll-In Phase: Up to 180 patients undergoing PCI per the Inclusion/Exclusion criteria; up to 3 roll-in patients per site.

Randomized Phase: Up to 425 patients undergoing PCI per the Inclusion/Exclusion criteria.

Data will be collected at baseline, during the PCI procedure, postprocedure, discharge, and 90 days post device removal.

All patients will have a follow-up visit at 90 days post-device removal.


More information about research and clinical trials


Door To Unloading with IMPELLA® CP System in Acute Myocardial Infarction to Reduce Infarct Size (DTU): A Prospective Feasibility Study

A multi-center, prospective randomized, two-arm feasibility trial to assess the potential role of unloading with the Impella CP prior to revascularization in reducing infarct size. The study design includes 1:1 randomization between: 1) Delay Arm: 30 minutes of unloading with Impella CP prior to primary percutaneous coronary intervention (PPCI); and 2) Immediate Arm: initiation of Impella CP unloading followed immediately by PPCI. Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasibility. The primary objective of this study is to evaluate whether the use of the Impella CP System for unloading of the left ventricle prior to PPCI has the potential to limit infarct size in patients presenting with STEMI. A secondary objective of the trial is to evaluate the need for 30 minutes of active left ventricular unloading prior to PPCI. Up to 50 subjects will be randomized int he study, 25 in each study arm.
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn’t make you feel small.  At Tufts Medical Center the patient is at the center of everything that we do.  This means we’re committed to providing the highest quality of care in a safe, friendly environment.

Learn more
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history